When is Immunotech Laboratories’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
Is Immunotech Laboratories overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Immunotech Laboratories pay dividends?
Immunotech Laboratories does not currently pay dividends.
What is Immunotech Laboratories’s EPS estimate?
Immunotech Laboratories’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immunotech Laboratories have?
Immunotech Laboratories has 574,965,000 shares outstanding.
Which hedge fund is a major shareholder of Immunotech Laboratories?
Currently, no hedge funds are holding shares in IMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunotech Laboratories
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California. As of June 14, 2017, Immunotech Laboratories, Inc. operates as a subsidiary of Enzolytics, Inc.